Zepbound for weight loss: what TikTok gets right and wrong

What did @_pandababyy actually say?

The creator appeared on a show and felt the need to correct a widespread rumor. "I am not on Ozempic. I'm on Monjaro, okay? That's 2.5" is the core of what they said. They also referenced people complaining their head looked too big for their body, and mentioned stopping Ozempic would be harmful to family members who need it. The statement was a public clarification, not a medical tutorial. That matters when we evaluate it.

The creator is distinguishing between two different GLP-1 based drugs, which is actually a meaningful distinction most people on social media flatten into one. Ozempic contains semaglutide. Mounjaro contains tirzepatide. These are not the same molecule, not the same mechanism, and not interchangeable. Getting that distinction right, even casually, is more than most influencers manage.

Does the science back this up?

Yes, mostly. Mounjaro (tirzepatide) and Ozempic (semaglutide) are genuinely different drugs, and the science supports treating them that way. Calling one the other is medically imprecise in ways that matter.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Semaglutide is a GLP-1 receptor agonist only. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 15 mg produced mean weight loss of around 20.9% of body weight over 72 weeks in adults with obesity. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg produced about 14.9% weight loss over 68 weeks. These are different drugs with different efficacy profiles, and confusing them does a disservice to patients trying to understand their options.

The 2.5 mg starting dose the creator mentions is the standard FDA-approved initiation dose for tirzepatide, used to minimize gastrointestinal side effects before titrating up.

What did they get wrong (or right)?

They got the drug distinction right. Mounjaro and Ozempic are not the same, and it matters. They also implicitly raised a real supply issue: GLP-1 medications have faced significant shortage problems affecting patients with type 2 diabetes who depend on them medically.

What is less clear from the transcript is whether the creator understands why these drugs work differently or whether they are simply defending themselves against a label they dislike. That is fine, but the framing of "I am not on Ozempic" as a correction sometimes implies one drug is more legitimate than the other. Both are FDA-approved medications for weight management when prescribed appropriately. Neither is shameful. Neither is a shortcut. The SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM) showed even liraglutide, an older GLP-1 drug, produced clinically significant weight loss with lifestyle intervention.

The shortage comment is also worth taking seriously. The American Diabetes Association and the FDA have both flagged access problems for insulin-dependent diabetics who lost supply to GLP-1 drugs prescribed off-label. That is a real ethical and logistical tension the creator touched on, however briefly.

What should you actually know?

If you are considering a GLP-1 drug for weight loss, the drug name matters, the dose matters, and the prescriber matters. Mounjaro and Ozempic are not the same drug, and their outcomes in clinical trials differ meaningfully. "I'm on Monjaro" is not a more acceptable answer than Ozempic, but it is a more accurate one if that is what the prescription actually says.

The 2.5 mg dose of tirzepatide mentioned by the creator is the starting dose in the approved titration schedule. Staying at that dose for longer than recommended or escalating too fast both carry risks, including nausea, vomiting, and gastrointestinal complications. None of that is covered in a 30-second TikTok clip, and that gap is the real problem with this content category.

The creator was not giving medical advice here. They were correcting a rumor about themselves. That is a very different thing, and judging it as a health tutorial would be unfair. But the comments section does not always make that distinction, and that is where the harm can sneak in.

• Tirzepatide and semaglutide work through different receptor pathways.
• SURMOUNT-1 data suggests tirzepatide produces greater average weight loss than semaglutide in head-to-head context studies.
• GLP-1 drug shortages have real consequences for patients with type 2 diabetes who are not using them for weight loss.
• Starting dose of tirzepatide is 2.5 mg, escalated monthly based on tolerability.